SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
LONDON, March 22, 2016 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, will be a major participant in the Drug Information Association’s 28th Annual EuroMeeting, taking place April 6-8, 2016, in Hamburg, Germany. The company will host a presentation in the Innovation Theatre and have a large presence in the exhibit hall of the Congress Center Hamburg.
“We are excited that we have reached the point in our company’s growth where we can support the DIA EuroMeeting at a significant level,” said Michael Britt, APCER Europe’s business unit leader and Global Head of Quality and Compliance. “The European clients that we have been serving since our founding helped us define our value proposition and build our firm into the global presence it is today.”
APCER’s presentation in the Innovation Theatre is titled “Redefining PV: From Pharmacovigilance to Patient Voice and Product Value.” It will explore how pharmacovigilance, when practiced with consistency and integrated tightly with medical affairs, can yield a rich source of real-world patient data that quantifies product value and demonstrates a competitive advantage for partnering and out-licensing deals, formulary decisions, and reimbursement rates.
APCER Life Sciences is active in the Drug Information Association around the world. In addition to the EuroMeeting, the company will be speaking at the DIA Innovations in Pharmacovigilance meeting in Mumbai, India, May 13-14, and at the 52nd DIA Annual Meeting in Philadelphia, Pennsylvania, USA, June 27-30. APCER is also exhibiting at the DIA Medical Affairs and Scientific Communications Annual Forum in Orlando, Florida, USA, this week.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; then contact APCER at one of their global offices.
Contact: Jill Notte Director, Global Marketing +1-609-436-4714
